Compare MCB & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCB | ELVN |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.2M | 1.1B |
| IPO Year | 2017 | 2020 |
| Metric | MCB | ELVN |
|---|---|---|
| Price | $91.73 | $25.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $97.50 | $41.00 |
| AVG Volume (30 Days) | 185.2K | ★ 1.6M |
| Earning Date | 01-20-2026 | 03-12-2026 |
| Dividend Yield | ★ 0.87% | N/A |
| EPS Growth | ★ 11.64 | N/A |
| EPS | ★ 6.62 | N/A |
| Revenue | ★ $277,514,000.00 | N/A |
| Revenue This Year | $29.07 | N/A |
| Revenue Next Year | $7.96 | N/A |
| P/E Ratio | $13.90 | ★ N/A |
| Revenue Growth | ★ 2.53 | N/A |
| 52 Week Low | $47.08 | $13.30 |
| 52 Week High | $96.75 | $29.98 |
| Indicator | MCB | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 65.29 | 61.29 |
| Support Level | $87.74 | $24.90 |
| Resistance Level | $96.75 | $28.69 |
| Average True Range (ATR) | 3.62 | 1.57 |
| MACD | 0.70 | -0.07 |
| Stochastic Oscillator | 74.08 | 41.15 |
Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.